• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伊马替尼和尼洛替尼诱发的慢性髓性白血病苔藓样疹：1例罕见病例报告

Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report.

作者信息

Sachdeva Meenakshi, Singh Jayanti, Dayal Surabhi, Gupta Aanchal

机构信息

Department of Dermatology, Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India.

Department of Pathology, Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India.

出版信息

Indian Dermatol Online J. 2023 Oct 5;15(3):492-495. doi: 10.4103/idoj.idoj_229_23. eCollection 2024 May-Jun.

DOI:10.4103/idoj.idoj_229_23
PMID:38845649
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11152493/
Abstract

Imatinib and nilotinib are inhibitors of tyrosine kinases (TKIs) generated from the bcr-abl fusion protein, c-Kit, and platelet-derived growth factor receptors. Cutaneous adverse effects (AEs) of TKI are the most frequent non-hematological sequelae. In our case, the common molecular target raises the possibility that cross-intolerance, in which similar AEs occur with both agents, can arise. We hereby report a rare case report on cross-intolerance of cutaneous AEs of imatinib and nilotinib in chronic myeloid leukemia.

摘要

伊马替尼和尼洛替尼是由bcr-abl融合蛋白、c-Kit和血小板衍生生长因子受体产生的酪氨酸激酶抑制剂（TKIs）。TKI的皮肤不良反应（AEs）是最常见的非血液学后遗症。在我们的病例中，共同的分子靶点增加了交叉不耐受的可能性，即两种药物都出现类似的AEs。我们在此报告一例慢性髓性白血病中伊马替尼和尼洛替尼皮肤AEs交叉不耐受的罕见病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/555b/11152493/a57dfa1bd7bd/IDOJ-15-492-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/555b/11152493/c96cb07d4bbd/IDOJ-15-492-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/555b/11152493/8770acf49e1c/IDOJ-15-492-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/555b/11152493/ec460b97b1cb/IDOJ-15-492-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/555b/11152493/a57dfa1bd7bd/IDOJ-15-492-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/555b/11152493/c96cb07d4bbd/IDOJ-15-492-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/555b/11152493/8770acf49e1c/IDOJ-15-492-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/555b/11152493/ec460b97b1cb/IDOJ-15-492-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/555b/11152493/a57dfa1bd7bd/IDOJ-15-492-g004.jpg

相似文献

1
Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report.伊马替尼和尼洛替尼诱发的慢性髓性白血病苔藓样疹：1例罕见病例报告
Indian Dermatol Online J. 2023 Oct 5;15(3):492-495. doi: 10.4103/idoj.idoj_229_23. eCollection 2024 May-Jun.
2
Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis.酪氨酸激酶抑制剂治疗慢性髓性白血病的血液学不良事件：一项系统评价与荟萃分析
Cancers (Basel). 2023 Aug 31;15(17):4354. doi: 10.3390/cancers15174354.
3
[Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia].[慢性髓性白血病对酪氨酸激酶抑制剂耐药患者中与BCR-ABL激酶结构域突变相关的变量]
Zhonghua Xue Ye Xue Za Zhi. 2020 Jun 14;41(6):469-476. doi: 10.3760/cma.j.issn.0253-2727.2020.06.006.
4
Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population.印度尼西亚慢性期慢性髓性白血病（CML）人群中酪氨酸激酶抑制剂（伊马替尼和尼洛替尼）的谷浓度与 BCR-ABL 比值的关系。
J Basic Clin Physiol Pharmacol. 2020 Aug 4;31(5):/j/jbcpp.2020.31.issue-5/jbcpp-2019-0315/jbcpp-2019-0315.xml. doi: 10.1515/jbcpp-2019-0315.
5
Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.LYN 和 PTEN 基因在慢性髓性白血病中的表达及其在治疗策略中的重要性。
Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):121-5. doi: 10.1016/j.bcmd.2013.09.002. Epub 2013 Oct 3.
6
[Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbès University Hospital Center].[西迪贝勒阿巴斯大学医院中心慢性髓性白血病治疗中使用的酪氨酸激酶抑制剂的不良反应患病率]
Ann Pharm Fr. 2022 Nov;80(6):932-942. doi: 10.1016/j.pharma.2022.03.004. Epub 2022 Apr 22.
7
Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.比较第二代酪氨酸激酶抑制剂和伊马替尼治疗慢性髓性白血病的皮肤不良反应：系统评价和荟萃分析。
Acta Oncol. 2023 Dec;62(12):1767-1774. doi: 10.1080/0284186X.2023.2263152. Epub 2023 Nov 25.
8
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.尼洛替尼：一种对BCR-ABL、KIT和PDGFR激酶具有活性的苯基氨基嘧啶衍生物。
Future Oncol. 2008 Oct;4(5):611-21. doi: 10.2217/14796694.4.5.611.
9
Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib.酪氨酸激酶抑制剂治疗慢性髓性白血病期间出现的毛发角化病样皮疹：文献综述及1例与伊马替尼相关病例报告
J Clin Med. 2023 Dec 20;13(1):32. doi: 10.3390/jcm13010032.
10
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.尼罗替尼（原AMN107）是一种高度选择性的BCR-ABL酪氨酸激酶抑制剂，对伊马替尼耐药和不耐受的慢性期费城染色体阳性慢性髓性白血病患者有效。
Blood. 2007 Nov 15;110(10):3540-6. doi: 10.1182/blood-2007-03-080689. Epub 2007 Aug 22.

引用本文的文献

1
5-Repurposed Drug Candidates Identified in Motor Neurons and Muscle Tissues with Amyotrophic Lateral Sclerosis by Network Biology and Machine Learning Based on Gene Expression.基于基因表达，通过网络生物学和机器学习在肌萎缩侧索硬化症的运动神经元和肌肉组织中鉴定出5种重新利用的候选药物。
Neuromolecular Med. 2025 Apr 3;27(1):24. doi: 10.1007/s12017-025-08847-z.

本文引用的文献

1
Imatinib-Induced Classical Lichen Planopilaris in Blaschko-Linear Distribution Leading to Cicatricial Alopecia.伊马替尼诱发的呈线状分布于布氏线的经典扁平苔藓样毛发扁平苔藓，导致瘢痕性脱发。
Indian Dermatol Online J. 2021 May 12;12(3):444-446. doi: 10.4103/idoj.IDOJ_536_20. eCollection 2021 May-Jun.
2
Imatinib mesylate-induced lichenoid drug eruption.甲磺酸伊马替尼诱发苔藓样药疹。
Cutis. 2017 Mar;99(3):189-192.
3
Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.慢性髓性白血病第二代和第三代酪氨酸激酶抑制剂的独特皮肤反应
Dermatology. 2016;232(1):122-5. doi: 10.1159/000437383. Epub 2015 Sep 10.
4
Lichenoid drug eruption due to imatinib mesylate.甲磺酸伊马替尼所致苔藓样药疹。
Int J Appl Basic Med Res. 2015 Jan-Apr;5(1):68-9. doi: 10.4103/2229-516X.149253.
5
Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.靶向治疗的皮肤不良反应：第一部分：细胞膜抑制剂。
J Am Acad Dermatol. 2015 Feb;72(2):203-18; quiz 219-20. doi: 10.1016/j.jaad.2014.07.032.
6
Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.酪氨酸激酶抑制剂（包括甲磺酸伊马替尼、尼洛替尼和达沙替尼）引起的皮肤不良反应。
Dermatol Ther. 2011 Jul-Aug;24(4):386-95. doi: 10.1111/j.1529-8019.2011.01431.x.
7
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.对不耐受伊马替尼的慢性或加速期慢性髓性白血病患者，尼洛替尼的交叉耐受最小。
Blood. 2011 May 26;117(21):5600-6. doi: 10.1182/blood-2010-11-318949. Epub 2011 Apr 5.
8
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.酪氨酸激酶抑制剂——药理学、代谢及副作用综述
Curr Drug Metab. 2009 Jun;10(5):470-81. doi: 10.2174/138920009788897975.
9
Indications for imatinib mesylate therapy and clinical management.甲磺酸伊马替尼治疗的适应证及临床管理。
Oncologist. 2004;9(3):271-81. doi: 10.1634/theoncologist.9-3-271.